Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study

Mads Hvid Poulsen*, Jørn Skibsted Jakobsen, Mike Allan Mortensen, Poul Flemming Høilund-Carlsen, Lars Lund

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

33 Downloads (Pure)

Resumé

Objective: The effect of curative treatment for oligometastatic prostate cancer patients is unsolved, both with regard to morbidity and mortality. With this study, we provide some of the first long-term follow-up data on progression and mortality in oligometastatic prostate cancer patients after curative treatment of their primary tumor. Methods: A cohort of 210 patients with diagnosed prostate cancer was established between 2008 and 2010. All patients were scheduled for intended curative treatment, and all underwent blinded18F-choline positron-emission tomography/computed tomography at inclusion prior to curative treatment. Upon unblinding, 12 patients (6%) were recategorized as being oligometastatic. They had a mean age of 64 years,median prostate-specific antigen of 18 ng/mL, and median Gleason score of 7. Six patients were staged as T3, one T2, and five T1. The patients had a medianof one bone metastasis (range 1–2). All underwent intended curative radiotherapy or prostatectomy. Mean follow-up was 10.1 (8.9–11.0) years. Results: During follow-up of the 12 patients, three (25%) had biochemical recurrence, two developed castration-resistant disease, and one died due to prostate cancer. Conclusion: Our results suggest that intended curative treatment of the primary tumor in oligometastatic prostate cancer may have a role in highly selected patients.

OriginalsprogEngelsk
TidsskriftResearch and Reports in Urology
Vol/bind11
Sider (fra-til)215-221
ISSN2253-2447
DOI
StatusUdgivet - 30. jul. 2019

Fingeraftryk

Prostatic Neoplasms
Neoplasms
Neoplasm Grading
Prostate-Specific Antigen
Choline

Citer dette

@article{74cbdefa8e704bd191d542f494aaf6d3,
title = "Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study",
abstract = "Objective: The effect of curative treatment for oligometastatic prostate cancer patients is unsolved, both with regard to morbidity and mortality. With this study, we provide some of the first long-term follow-up data on progression and mortality in oligometastatic prostate cancer patients after curative treatment of their primary tumor. Methods: A cohort of 210 patients with diagnosed prostate cancer was established between 2008 and 2010. All patients were scheduled for intended curative treatment, and all underwent blinded18F-choline positron-emission tomography/computed tomography at inclusion prior to curative treatment. Upon unblinding, 12 patients (6{\%}) were recategorized as being oligometastatic. They had a mean age of 64 years,median prostate-specific antigen of 18 ng/mL, and median Gleason score of 7. Six patients were staged as T3, one T2, and five T1. The patients had a medianof one bone metastasis (range 1–2). All underwent intended curative radiotherapy or prostatectomy. Mean follow-up was 10.1 (8.9–11.0) years. Results: During follow-up of the 12 patients, three (25{\%}) had biochemical recurrence, two developed castration-resistant disease, and one died due to prostate cancer. Conclusion: Our results suggest that intended curative treatment of the primary tumor in oligometastatic prostate cancer may have a role in highly selected patients.",
keywords = "Oligometastases, Prostate cancer, Treatment",
author = "Poulsen, {Mads Hvid} and Jakobsen, {J{\o}rn Skibsted} and Mortensen, {Mike Allan} and H{\o}ilund-Carlsen, {Poul Flemming} and Lars Lund",
year = "2019",
month = "7",
day = "30",
doi = "10.2147/RRU.S190140",
language = "English",
volume = "11",
pages = "215--221",
journal = "Research and Reports in Urology",
issn = "2253-2447",
publisher = "Dove Medical Press Ltd.(Dovepress)",

}

Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study. / Poulsen, Mads Hvid; Jakobsen, Jørn Skibsted; Mortensen, Mike Allan; Høilund-Carlsen, Poul Flemming; Lund, Lars.

I: Research and Reports in Urology, Bind 11, 30.07.2019, s. 215-221.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Does therapy of the primary tumor matter in oligometastatic prostate cancer? A prospective 10-year follow-up study

AU - Poulsen, Mads Hvid

AU - Jakobsen, Jørn Skibsted

AU - Mortensen, Mike Allan

AU - Høilund-Carlsen, Poul Flemming

AU - Lund, Lars

PY - 2019/7/30

Y1 - 2019/7/30

N2 - Objective: The effect of curative treatment for oligometastatic prostate cancer patients is unsolved, both with regard to morbidity and mortality. With this study, we provide some of the first long-term follow-up data on progression and mortality in oligometastatic prostate cancer patients after curative treatment of their primary tumor. Methods: A cohort of 210 patients with diagnosed prostate cancer was established between 2008 and 2010. All patients were scheduled for intended curative treatment, and all underwent blinded18F-choline positron-emission tomography/computed tomography at inclusion prior to curative treatment. Upon unblinding, 12 patients (6%) were recategorized as being oligometastatic. They had a mean age of 64 years,median prostate-specific antigen of 18 ng/mL, and median Gleason score of 7. Six patients were staged as T3, one T2, and five T1. The patients had a medianof one bone metastasis (range 1–2). All underwent intended curative radiotherapy or prostatectomy. Mean follow-up was 10.1 (8.9–11.0) years. Results: During follow-up of the 12 patients, three (25%) had biochemical recurrence, two developed castration-resistant disease, and one died due to prostate cancer. Conclusion: Our results suggest that intended curative treatment of the primary tumor in oligometastatic prostate cancer may have a role in highly selected patients.

AB - Objective: The effect of curative treatment for oligometastatic prostate cancer patients is unsolved, both with regard to morbidity and mortality. With this study, we provide some of the first long-term follow-up data on progression and mortality in oligometastatic prostate cancer patients after curative treatment of their primary tumor. Methods: A cohort of 210 patients with diagnosed prostate cancer was established between 2008 and 2010. All patients were scheduled for intended curative treatment, and all underwent blinded18F-choline positron-emission tomography/computed tomography at inclusion prior to curative treatment. Upon unblinding, 12 patients (6%) were recategorized as being oligometastatic. They had a mean age of 64 years,median prostate-specific antigen of 18 ng/mL, and median Gleason score of 7. Six patients were staged as T3, one T2, and five T1. The patients had a medianof one bone metastasis (range 1–2). All underwent intended curative radiotherapy or prostatectomy. Mean follow-up was 10.1 (8.9–11.0) years. Results: During follow-up of the 12 patients, three (25%) had biochemical recurrence, two developed castration-resistant disease, and one died due to prostate cancer. Conclusion: Our results suggest that intended curative treatment of the primary tumor in oligometastatic prostate cancer may have a role in highly selected patients.

KW - Oligometastases

KW - Prostate cancer

KW - Treatment

U2 - 10.2147/RRU.S190140

DO - 10.2147/RRU.S190140

M3 - Journal article

C2 - 31440485

AN - SCOPUS:85070521336

VL - 11

SP - 215

EP - 221

JO - Research and Reports in Urology

JF - Research and Reports in Urology

SN - 2253-2447

ER -